1
: Synairgen plc (LSE: SNG), the respiratory company developing inhaled interferon beta (IFN-beta) for the treatment of severe viral lung infections, today announces results from the Home Cohort of its SG016 Phase II trial of SNG001 in SARS-CoV-2 infected patients and data from the combined analysis of the Hospital and Home Cohorts.
SNG001 is a formulation containing IFN-beta for nebulisation, allowing it to be delivered directly into patients’ lungs. A number of studies have reported that the SARS-CoV-2 virus suppresses natural production of IFN-beta and prevents induction of anti-viral responses by infected cells. Furthermore, some people have deficiencies in antiviral IFN signalling that make them more vulnerable to spread of the virus from the nose into the lungs where it can cause severe breathing difficulties. These findings provide a rationale to deliver IFN-beta directly to the surface epithelial cells of the lungs, the primary site of virus infection in the lungs, to pr
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.
April 21, 2021 • 3:52 pm CDT (Precision Vaccinations)
France-based Valneva SE announced it had initiated a pivotal Phase 3 clinical trial for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.
The Phase 3 trial, “Cov-Compare” (VLA2001-301), will compare VLA2001 against AstraZeneca’s COVID-19 conditionally approved vaccine, known as Vaxzevria in a comparative immunogenicity trial. Approximately 4,000 participants located in the United Kingdom (UK) will receive two doses of either vaccine administered in a four-week interval.
The primary endpoint of Cov-Compare will be to determine the immune response (Geometric Mean Titer (GMT)) of SARS-CoV-2-specific neutralizing antibodies) two weeks after immunization. The trial is powered to demonstrate the superiority of VLA2001 in terms of GMT ratio (VLA2001/Vaxzevria).
The 12 symptoms that indicate you might have long Covid nottinghampost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nottinghampost.com Daily Mail and Mail on Sunday newspapers.
Sam Lisco
It’s true that we learn from our mistakes, but given the choice, wouldn’t we all prefer to learn from the mistakes –
and the achievements – of others.
Samantha Liscio, 2020 Canadian CIO of the Year (public sector), makes a powerful case for vicarious learning as a guest on ITWC’s podcast series,
Series host, ITWC CIO Jim Love, opens the 45-minute podcast with an introduction to Liscio, former Chief Technology and Innovation Officer for Ontario’s Workplace Safety and Insurance Board, and incoming Chief Information and Technology Officer for the UK’s National Institute for Health Research (NIHR) Clinical Research Network (CRN). A digital transformation specialist with 20 years of experience in IT leadership roles, she comes to the table with a deep love of technology and a personal playbook for success.